Evidence map›Paper›PMID 30635715›Full record

ReviewEuropean archives of psychiatry and clinical neuroscience2019

Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain.

Gabrielle Campbell, Emily Stockings, Suzanne Nielsen

Abstract readReview
PubMed Publisher
In one paragraph

Review in European archives of psychiatry and clinical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Cannabis use and mental health: risks and benefits.European archives of psychiatry and clinical neuroscience · 2019
    Article
  16. Article
  17. Occupational Allergies to Cannabis.The journal of allergy and clinical immunology. In practice
    Review
  18. Article
  19. Medicinal cannabis: new challenges for the anesthesiologist.Brazilian journal of anesthesiology (Elsevier)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gabrielle CampbellNational Drug and Alcohol Research Centre (NDARC), Faculty of Medicine, UNSW Sydney, 22-32 King Street, Randwick, NSW, 2031, Australia. g.campbell@unsw.edu.au.ORCID http://orcid.org/0000-0002-0851-0748
Emily StockingsNational Drug and Alcohol Research Centre (NDARC), Faculty of Medicine, UNSW Sydney, 22-32 King Street, Randwick, NSW, 2031, Australia.ORCID http://orcid.org/0000-0001-5349-951X
Suzanne NielsenMonash Addiction Research Centre, Eastern Health Clinical School, Faculty of Medicine Nursing and Health Sciences, Monash University, Level 2, 5 Arnold Street, Box Hill, VIC, 3128, Australia.ORCID http://orcid.org/0000-0001-5341-1055
UNSW Sydney · AUEastern Health · AU

Funding

National Health and Medical Research Council 1104600National Health and Medical Research Council 1119992National Health and Medical Research Council 113243
6 · The paper itself

Abstract

The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including limitations of randomised control trials in the field, limits on generalisability of previous findings and common issues such as problems with measurements of dose and type of cannabinoids. We discuss future directions for medicinal cannabinoid research, including addressing limitations in trial design; developing frameworks to monitor for use disorder and other unintended outcomes; and considering endpoints other than 30% or 50% reductions in pain severity.

Indexed as

Cannabinoid Receptor ModulatorsCannabinoidsChronic PainHumansMedical MarijuanaCannabinoid Receptor ModulatorsCannabinoidsMedical MarijuanaCannabisCannabis-based medicinesChronic painMedical cannabis

Identifiers

PMID30635715
OpenAlexW2908926404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.